RegulatoryCompany release

Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date

🇺🇸 Apnimed, Inc. (APMD) · Mon 16 Nov 2026

Apnimed says its new drug application for AD109 (proposed name Oxnimbi) in adult obstructive sleep apnoea remains under FDA review, as it reports a Q3 net loss of $29.5m.

Apnimed said on 16 November 2026 that the US Food and Drug Administration is still reviewing its new drug application for AD109, a combination of aroxybutynin and atomoxetine proposed for adults with obstructive sleep apnoea. The proposed brand name is Oxnimbi. The agency's PDUFA goal date is 28 February 2027.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Apnimed, Inc. ↗

Article written by VigiEye from the official source (Apnimed, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →